Market Closed - Nasdaq Copenhagen 10:59:35 2024-05-08 am EDT 5-day change 1st Jan Change
338 DKK -2.87% Intraday chart for Gubra A/S +14.19% +170.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss CI
Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. CI
Gubra Concludes the Research Agreement with Silence Therapeutics plc CI
Gubra and Boehringer Ingelheim Sign 4Th Partnership, Expanding Their Successful Obesity Treatment Discovery Collaboration CI
Gubra A/S Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist for the Treatment of Obesity CI
Gubra A/S Announces Board Appointments CI
Gubra Raises Earnings Guidance for Full-Year 2023 CI
Denmark's Gubra Opens First US Office Under Expansion Strategy MT
Gubra A/S Opens Its First US Office in Boston CI
Gubra Seeks UK Regulatory Approval to Begin Human Trial for Anti-Obesity Drug MT
Gubra A/S Submits Clinical Trial Application for First-In-Human Amylin Trial CI
Tranche Update on Gubra A/S's Equity Buyback Plan announced on June 30, 2023. CI
Gubra Announces Termination of Collaboration with Bayer AG CI
Gubra A/S Raises Financial Guidance for Full-Year 2023 CI
Gubra A/S commences an Equity Buyback Plan for 1,180,424 shares, under the authorization approved on March 16, 2023. CI
Gubra A/S acquired Minigut Aps for DKK 5.96 million. CI
Gubra A/S Announces Updates to Its Pipeline CI
Gubra A/S and Boehringer Ingelheim Share Phase 1 Results for BI 1820237 CI
Gubra A/S Provides Revenue Guidance for the Year 2023 CI
Danish Biotech Gubra's IPO Overallotment Option Partly Exercised MT
Gubra A/S(CPSE:GUBRA) added to OMX Nordic All-Share Index CI
Gubra A/S has completed an IPO in the amount of DKK 500.00005 million. CI
Gubra A/S has filed an IPO in the amount of DKK 500.00005 million. CI
Chart Gubra A/S
More charts
Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. GUBRA Stock
  4. News Gubra A/S
  5. Danish Biotech Gubra's IPO Overallotment Option Partly Exercised
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW